Genomic Health (GHDX) Oncotype DX Score Test Data Positive

Genomic Health, Inc. (NASDAQ:GHDX) recently announced outcomes from 10 trials, which underscore the efficiency of the Oncotype DX Breast Recurrence Score test and Oncotype DX DCIS Score test for breast cancer. Notably, Ductal carcinoma in situ, also known as DCIS, is the most common type of non-invasive breast cancer

Per a report by BREASTCANCER.ORG the Oncotype DX test analyzes genes to estimate the response of cancer patients post treatment. In fact the report suggests that, the results of the Oncotype DX test help the patients to decide about whether or not to have chemotherapy to treat an early-stage breast cancer or radiation therapy to treat DCIS.

Genomic Health’s flagship product Oncotype DX Breast Recurrence Score test helps predict the probability of chemotherapy benefit. The Oncotype DX Breast DCIS Score test predicts the possibility of recurrence of a pre-invasive form of breast cancer — DCIS.

The outcome shows that the Oncotype DX Breast Recurrence Score test predicts the clinical response of Neoadjuvant Hormonal Therapy in improving surgical results.

The results also show that many node-positive breast cancer patients can avoid chemotherapy based on the Recurrence Score Test result.

Also, the company announced that the new American Joint Committee on Cancer (AJCC) Prognostic Stage Groups will add the Oncotype DX Breast Recurrence Score, hormonal status (ER, PR) and HER2 status to nodal status, tumor size and tumor grade for staging breast cancer effective January 2018.

Developments in Oncotype DX Breast Recurrence Score Test

Genomic Health and Biocartis Group NV signed an agreement to develop an in vitro diagnostic (IVD) version of the Oncotype DX Breast Recurrence Score test on Biocartis' proprietary Idylla platform in September.

In the same month, Genomic Health announced that new data shows additional evidence of the unmatched value of the Oncotype DX Breast Recurrence Scoretest in predicting outcomes in early-stage breast cancer patients accurately.

Focus on International Markets to Boost Growth

Having established a strong foothold in the U.S. market, Genomic Health is now making considerable headway in the international arena. The company’s Oncotype DX breast cancer tests are available in 86 countries, courtesy of various collaborations.

Market Trends Buoy Optimism

According to a report by GBI Research, the global breast cancer therapeutics market is estimated to reach a worth of $17.2 billion by 2021, at a CAGR of 7.3%. Considering the solid prospects of the market, we believe the latest agreement is a strategic fit.

Stock Performance Solid

In the past month, Genomic Health has been trading above the broader industry. The stock has gained 3.5%, in comparison with the broader industry’s 1.5% gain.

Zacks Rank & Key Picks

Genomic Health carries a Zacks Rank #3 (Hold).

A few better-ranked medical stocks are athenahealth, Inc. (NASDAQ:ATHN) , Align Technology, Inc. (NASDAQ:ALGN) and Myriad Genetics, Inc. (NASDAQ:MYGN) . Notably, athenahealth, Align Technology and Myriad Genetics sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

athenahealth has a long-term expected earnings growth rate of 22.3%. The stock has rallied roughly 36% over a year.

Align Technology has a long-term expected earnings growth rate of 28.9%. The stock has gained 135.7% in a year.

Myriad Genetics has a long-term expected earnings growth rate of 15%. The stock has gained 81.2% in a year’s time.

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>